Expanding Opportunities with Hybrozyme™ Platform Technology: Alteogen Registers in 5 Countries and Prepares for Future Growth
Registered in 5 countries, being reviewed in major countries and preparing for registration Ensures the possibility that the Hybrozyme™ platform technology will be expanded in different directions in the future (Photo = Alteogen) [바이오타임즈] Alteogen, a bio-platform company, announced that its patent office has completed domestic patent registration for a mixed formulation of ALT-B4, a […]
Pharmaceutical Industry Trends at AACR 2024: New Anticancer Drug Research Revealed
[메디칼업저버 신형주 기자] With the AACR due to take place next month, where early research and pre-clinical stage information in the anticancer field will be published to provide insight into the future of anticancer drugs, attention is paid to industry submission trends domestic pharmaceuticals. The annual conference of the American Association for Cancer Research 2024 […]
Samsung Invests in Biopharmaceutical Company BrickBio Through Life Science Fund: Expanding Opportunities in Protein Engineering Technology
Samsung announced on the 19th that it would invest in BrickBio, an American company that develops biopharmaceuticals, through the Life Science Fund, which was created to develop new technologies and businesses in the field of life science. Through this investment, Samsung will not only explore new biobusiness opportunities, but also develop business opportunities related to […]
ABL Bio CEO Announces Domestic Patent Approval for BCMA Single Antibody Development
ABL Bio (CEO Lee Sang-hoon) announced on the 8th that it has completed the domestic patent registration of a BCMA (anti-B cell maturation antigen) single antibody. BCMA is a protein that is overexpressed in multiple myeloma. The company explained that since many patients with multiple myeloma relapse even if they respond to existing treatments, there […]
Dong-A ST Acquires Aptis, Specializing in ADC Drugs: New Growth Engine in R&D Sector
Dong-A ST (CEO Kim Min-young) announced on the 20th that it has acquired AbTis, a company specializing in antibody conjugated (ADC) drugs. Dong-A ST intends to secure a new growth engine in the research and development (R&D) sector by acquiring the management rights of Aptis and its new approach, technology and pipeline of the 3rd […]
Expanding Margins and JV Deals: PRINC’s Push into the Beauty Business
Expanding Business and Positive Q3 Results for PRINC By: [Journalist’s Name] Stock dimension – PRINC The beauty business is the focus of attention for PRINC as it seeks to expand and increase margins. A potential JV deal with additional partners could bring a big surprise for the company. The Q3 budget has shown positive results, […]
Celltrion Group Chairman Seo Jeong-jin Announces Merger Approval and Future Sales Expectations at 2023 Press Conference
Chairman Seo Jeong-jin of the Celltrion Group announced at a recent press conference that the merger between Celltrion and Celltrion Healthcare has been approved and will be completed this year. He also mentioned that Celltrion Healthcare’s sales for next year are projected to be around 3.5 trillion won. Additionally, after the merger, the operating profit […]
Merck & Daiichi Sankyo Sign $22 Billion Agreement for Antibody Drug Conjugates
Merck Signs Global Development and Commercialization Agreement with Daiichi Sankyo In a major deal, Merck & Co (MSD) of the United States has announced a global development and commercialization agreement with Japan-based Daiichi Sankyo. The agreement is focused on three types of antibody drug conjugates (ADCs) developed by Daiichi Sankyo. With an upfront payment of […]
ABL Bio Secures Chinese Patent and Market Opportunities for Anti-ROR1 Monoclonal Antibodies until 2039
ABL Bio Secures Chinese Patent for Anti-ROR1 Monoclonal Antibodies Guaranteed rights in China for anti-ROR1 monoclonal antibodies and their use until 2039 ABL Bio, led by CEO Lee Sang-hoon, a specialized company in bispecific antibodies, announced the successful registration of a Chinese patent for their anti-ROR1 antibody. This antibody effectively inhibits ROR1, a protein found […]
Exploring New Frontiers in Antibiotic Treatment: Collaborative Research on Bacteriophage Therapy with LegoChem Bio
Microbiotics and LegoChem Bio Collaborate on Bacteriophage Treatment Research In an effort to find alternatives to traditional antibiotic treatments, Microbiotics CEO, Dong-Eun Yong, announced a collaborative research agreement with LegoChem Bio. The goal of the partnership is to explore the use of bacteriophage treatment, which has the potential to go beyond current antibiotic therapies. The […]
